Polyclonal Antibody to Growth Regulated Oncogene Beta (GROb)
| Code | Size | Price |
|---|
| PAB603Mu07-20ul | 20ul | £82.00 |
Quantity:
| PAB603Mu07-100ul | 100ul | £152.00 |
Quantity:
| PAB603Mu07-200ul | 200ul | £204.00 |
Quantity:
| PAB603Mu07-1ml | 1ml | £464.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Mouse
Applications:
- Immunocytochemistry (ICC)
- Immunohistochemistry (IHC)
- Immunoprecipitation (IP)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
GROb; SCYB2; MIP2; GRO2; MIP2a; MGSAb; CINC2a; HSF; Macrophage inflammatory protein 2-alpha; Hematopoietic synergistic factor; Growth Regulated Oncogene Beta
Buffer Formulation:
PBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
Item Name:
Chemokine (C-X-C Motif) Ligand 2
Reactivity:
Ra;
Source:
Polyclonal antibody preparation
Usage:
Western blotting: 0.2-2ug/mL;1:250-2500
Immunohistochemistry: 5-20ug/mL;1:25-100
Immunocytochemistry: 5-20ug/mL;1:25-100
Optimal working dilutions must be determined by end user.
Immunohistochemistry: 5-20ug/mL;1:25-100
Immunocytochemistry: 5-20ug/mL;1:25-100
Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Growth Regulated Oncogene Beta (GROb) | EPB603Mu51 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||